Journal of Substance Abuse Treatment

Article	Citations
C2: editorial board	123
Barriers to accessing treatment for substance use after inpatient managed withdrawal (Detox): A qualitative study	85
JSAT call for papers for special issue: Stimulant use disorder	85
Community perspectives on supervised consumption sites: Insights from four U.S. counties deeply affected by opioids	75
Substance use disorders among older populations: What role do race and ethnicity play in treatment and completion?	60
The impact of military sexual trauma and gender on receipt of evidence-based medication treatment among veterans with opioid use disorder	57
Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings	52
A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail	51
Augmenting substance use treatment in the drug court: A pilot randomized trial of peer recovery support	50
A qualitative study of service engagement and unmet needs among unstably housed people who inject drugs in Massachusetts	50
The new services that opioid treatment programs have adopted in response to COVID-19	49
Integrating substance use care into primary care for adolescents and young adults: Lessons learned	49
C2: editorial board	48
Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders	45
Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data	44
Views of barriers and facilitators to continuing methadone treatment upon release from jail among people receiving patient navigation services	43
Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail	42
Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up	41
Experiences of stigma among individuals in recovery from opioid use disorder in a rural setting: A qualitative analysis	39
Serial mediation analysis of treatment-specific processes in two contrasting alcohol treatments	38
Education and careers were our way out	36
What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings	35
C2: editorial board	33
Al-Anon Intensive Referral (AIR): A qualitative formative evaluation for implementation	31
What is the relapse risk during treatment? Survivor analysis of single and multiple relapse events in inpatients with alcohol use disorder as part of an observational study	31

Massachusetts Justice Community Opioid Innovation Network (MassJCOIN)	31
Use of non–prescribed buprenorphine in the criminal justice system: Perspectives of individuals recently released from incarceration	31
Association between industry sponsorship and author conflicts of interest with outcomes of systematic reviews and meta-analyses of interventions for opioid use disorder	30
Emergency department interventions for opioid use disorder: A synthesis of emerging models	30
Incarceration and compulsory rehabilitation impede use of medication for opioid use disorder and HIV care engagement in Vietnam	30
A randomized clinical trial evaluating the impact of counselor training and patient feedback on substance use disorder patients' sexual risk behavior	29
Targeting women veteran's stress-induced drinking with cognitive reappraisal: Mechanisms and moderators of change	28
Stepped-wedge randomized controlled trial of a novel opioid court to improve identification of need and linkage to medications for opioid use disorder treatment for court-involved adults	28
Can nicotine replacement therapy be personalized? A statistical learning analysis	28
Suboptimal nonmedical qualities of primary care linked with care avoidance among people who use drugs in a Canadian setting amid an integrated health care reform	28
Using machine learning to identify predictors of imminent drinking and create tailored messages for at-risk drinkers experiencing homelessness	28
Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting	26
Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers	26
Adapting methadone inductions to the fentanyl era	25
Facing the future of substance use disorders treatment in Vietnam – A case study for international development and cooperation	25
Improving geographic access to methadone clinics	24
Using machine learning to examine predictors of treatment goal change among individuals seeking treatment for alcohol use disorder	24
Tobacco smoking and nicotine dependence among patients with respiratory diseases in Vietnam: Status and correlated factors	24
Addressing adolescent substance use in an urban pediatric federally qualified health center	24
Connecting and disconnecting: Experiences of people with opioid use disorder in intensive outpatient treatment	24
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)	24
The impact of social network dynamics on engagement in drug use reduction programs among men and women who use drugs	24
A randomized clinical trial of strengths-based case management to link emergency department patients to opioid use disorder treatment	23
Mobile-based brief interventions targeting cannabis-impaired driving among youth: A Delphi study	23
National trends in substance use treatment admissions for opioid use disorder among adults experiencing homelessness	23
Frequency and recency of non-medical opioid use and death due to overdose or suicide among individuals assessed for risky substance use: A national registry study in Sweden	23
The impact of COVID-19 on substance use disorder treatment in California: Service providers' perspectives	23
Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder	22
Latent class analysis of self-reported substance use during incarceration: Gender differences and associations with emotional distress and aggressiveness	22
An exploration of thriving over time in recovery	22
Drug court utilization of medications for opioid use disorder in high opioid mortality communities	22
C2: editorial board	21
Adapting and scaling a single site DEA X-waiver training program to a statewide initiative: Implementing GetWaiveredTX	20
Recovering from substance use disorders during the early months of the COVID-19 pandemic: A mixed-methods longitudinal study of women in Kansas City	20
Knowledge, attitudes, and behaviors related to the fentanyl-adulterated drug supply among people who use drugs in Oregon	20
Engagement patterns with a digital therapeutic for substance use disorders: Correlations with abstinence outcomes	20
Scoping review of interventions to link individuals to substance use services at discharge from jail	20
Corrigendum to “Feasibility and acceptability of mindful recovery opioid use care continuum (M-ROCC): A concurrent mixed methods study” [Journal of Substance Abuse Treatment 130 (2021) 108415]	19
Associations between prescription and illicit stimulant and opioid use in the United States, 2015–2020	19
Contingency management for treatment attendance: A meta-analysis	19
The impact of COVID-19 on health care professionals who are exposed to drug-related deaths while supporting clients experiencing addiction	19
Patterns of enrollment in a New Orleans women's substance use rehabilitation center	19
Emotion dysregulation and hazardous drinking in relation to suicidal ideation among Spanish-speaking Latinx daily-smokers	19
Implementation of buprenorphine initiation and warm handoff protocols in emergency departments: A qualitative study of Pennsylvania hospitals	19
Recidivism prevention for impaired driving: Longitudinal 5-year outcomes from Quebec's severity-based intervention assignment program	19
C2: editorial board	19
Increased utilization of buprenorphine and methadone in 2018 compared to 2015 among Seattle-area persons who inject drugs	19
Associations between patient experience and clinical outcomes in substance use disorder clinics: Findings from the veterans outcomes assessment survey	19
Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study	19
Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study	19

Beyond harm-producing versus harm-reducing: A qualitative meta-synthesis of people who use drugs' perspectives of and experiences with the extramedical use and diversion of buprenorphine	18
A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, he	18
Racial disparities in linkage to care among patients with substance use disorders	18
Where did the specialty behavioral health workforce grow between 2011 and 2019? Evidence from census data	18
SMART Recovery International and COVID-19: Expanding the reach of mutual support through online groups	18
Comparison of self-reported substance use with biological testing among treatment-seeking patients with opioid use disorder	17
Value of family involvement in substance use disorder treatment: Aligning clinical and financing priorities	17
Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19	17
TOC (update)	17
Alcohol and drug use among bartenders: An at risk population?	17
Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder	17
C2: editorial board	17
Cognitive insight, medication adherence and methamphetamine cessation in people enrolled in a pharmacotherapy trial for methamphetamine use	17
C2: editorial board	17
Mobile low-threshold buprenorphine integrated with infectious disease services	16
Follow-up after ED visits for opioid use disorder: Do they reduce future overdoses?	16
The effect of nicotine dependence and withdrawal symptoms on use of nicotine replacement therapy: Secondary analysis of a randomized controlled trial in primary care	16
Mobile methadone medication units: A brief history, scoping review and research opportunity	16
TOC (update)	16
Predictive validity of the New York State Level of Care for Alcohol and Drug Treatment Referral (LOCADTR) for continuous engagement in treatment among individuals recommended for outpatient care	16
Developing a cascade of care for opioid use disorder among individuals in jail	16
TOC (update)	16
Consumer access to buprenorphine and methadone in certified community behavioral health centers: A secret shopper study	16
Prescribing buprenorphine for opioid use disorder in primary care: A survey of French general practitioners in the Sentinelles network	15
Reducing Opioid Mortality in Illinois (ROMI): A case management/peer recovery coaching critical time intervention clinical trial protocol	15
Introduction to a Special Issue: Care and treatment for substance use disorders: Studies from around the world	15
Alcohol use disorder and treatment receipt among individuals aged 50 years and older: Other substance use and psychiatric correlates	15
Patient-centered primary care and receipt of evidence-based alcohol-related care in the national Veterans Health Administration	15
How emergency department visits for substance use disorders have evolved during the early COVID-19 pandemic	15
The short-term effectiveness of real-time video counselling on smoking cessation among residents in rural and remote areas: An interim analysis of a randomised trial	15
C2: editorial board	15
Parental status and characteristics of women in substance use treatment services: Analysis of electronic patient records	15
Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder	15
Client attitudes toward virtual treatment court	15
Associations between relationship quality and treatment-related stress among couples receiving methadone for opioid use disorder	15
Qualitative characterizations of misinformed disclosure reactions to medications for opioid use disorders and their consequences	15
The role of recovery housing during outpatient substance use treatment	14
Fostering MOUD use in justice populations: Assessing the comparative effectiveness of two favored implementation strategies to increase MOUD use	14
Treatment access for opioid use disorder in pregnancy among rural and American Indian communities	14
Ensuring access to high-quality substance use disorder treatment for Medicaid enrollees: A qualitative study of diverse stakeholders’ perspectives	14
Gender disparities in access and retention in outpatient methadone treatment for opioid use disorder in low-income urban communities	14
The effect of cannabis policies on treatment outcomes for cannabis use among U.S. adults	14
Association of facility characteristics and substance use disorder outcomes at discharge from residential treatment	14
“It could potentially be dangerous... but nothing else has seemed to help me.”: Patient and clinician perspectives on benzodiazepine use in opioid agonist treatment	14
Accessibility of substance use treatment: A qualitative study from the non-service users' perspective	13
Precision dosing of methadone during pregnancy: A pharmacokinetics virtual clinical trials study	13
Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention	13
Treatment options and shared decision-making in the treatment of opioid use disorder: A scoping review	13
TOC (update)	13
Baseline executive functions and receiving cognitive rehabilitation can predict treatment response in people with opioid use disorder	13
Opioid relapse and MOUD outcomes following civil commitment for opioid use	13
Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes	13
A systematic literature review of clinical trials and therapeutic applications of ibogaine	12
Managing substance use for clients with serious mental illnesses: Knowledge, attitude, and training challenges among outpatient behavioral health providers in California, Ohio, and New York	12
Adult emergency department naloxone education and prescription program: Video and pamphlet education comparison	12
Substance use among women who are pregnant: Examining treatment completion by race and ethnicity	12
Experiences of stigma in hospitals with addiction consultation services: A qualitative analysis of patients' and hospital-based providers' perspectives	12
Opium tincture-assisted treatment for opioid use disorder: A systematic review	12
Behavioral activation for depression delivered by drug and alcohol treatment workers: A pilot randomized controlled trial	12
Perspectives on preconception health among formerly incarcerated women with substance use disorders	12
Changes in methadone take-home dosing before and after COVID-19	12
A cohort study examining the relationship among housing status, patient characteristics, and retention among individuals enrolled in low-barrier-to-treatment-access methadone maintenance treatment	12
TOC (update)	12
Health economic analyses of the justice community opioid innovation network (JCOIN)	12
“In their mind, they always felt less than”: The role of peers in shifting stigma as a barrier to opioid use disorder treatment retention	12
Timing of smoking cessation treatment integrated into outpatient treatment with medications for opioid use disorder: Feasibility trial	11
TOC (update)	11
Characterizing nicotine withdrawal in smokers experiencing homelessness	11
Emergency department utilization by individuals with opioid use disorder who were recently incarcerated	11
Feasibility and early experience of a novel multidisciplinary alcohol-associated liver disease clinic	11
Diagnostic remission of substance use disorders: Racial differences and correlates of remission in a nationally representative sample	11
Motivational interviewing telephone counseling to increase postpartum maintenance of abstinence from tobacco	11
From there to here: A journey through substance use disorder, prison, and recovery	11
Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma	11
TOC (update)	11
Beliefs related to health care incentives: Comparison of substance use disorder treatment providers, medical treatment providers, and a public sample	11
Comparative outcomes for Black children served by the Sobriety Treatment and Recovery Teams program for families with parental substance abuse and child maltreatment	11
Poking the bear: The inapplicability of the RNR principles for justice-involved women	11
Corrigendum to “Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse” [Journal of Substance Abuse Treatment 131 (2021) 108447]	11
TOC (update)	11

Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic	11
Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: A state-level trends analysis	11
Successful transfer of stable patients on opioid agonist therapies from specialty addiction treatment to primary care settings in Ukraine: A pilot study	11
The Emergency Department Longitudinal Integrated Care (ED-LINC) intervention targeting opioid use disorder: A pilot randomized clinical trial	11
SBIRT administered by mental health counselors for hospitalized adults with substance misuse or disordered use: Evaluating hospital utilization and costs	11
The impact of race, gender, and heroin use on opioid addiction stigma	11
Traditions and Connections for Urban Native Americans (TACUNA): Utilizing community-based input to develop an opioid prevention intervention for urban American Indian/Alaska Native emerging adults	11
Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder	11
Cascade of care for office-based buprenorphine treatment in Bronx community clinics	10
Modeling the cost and impact of injectable opioid agonist therapy on overdose and overdose deaths	10
A scoping review of alcohol, tobacco, and other drug use treatment interventions for sexual and gender minority populations	10
Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing	10
Racial differences in overdose training, naloxone possession, and naloxone administration among clients and nonclients of a syringe services program	10
Trends and age-related disparities in opioid use disorder treatment admissions for adolescents and young adults	10
Gender differences in patient outcomes following drug abuse treatment in Afghanistan: Results from a new evaluation	10
A pilot randomized trial of CBT4CBT for women in residential treatment for substance use disorders	10
A spatio-temporal Bayesian model to estimate risk and evaluate factors related to drug-involved emergency department visits in the greater Baltimore metropolitan area	10
Pre-exposure prophylaxis awareness, acceptability and potential stigma among medical and non-medical clinic staff in methadone treatment settings in northern New Jersey: The key role of non-medical st	10
Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review	10
Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year	10
A randomized pilot trial of a mobile phone–based brief intervention with personalized feedback and interactive text messaging to reduce driving after cannabis use and riding with a cannabis impaired d	10
Factors associated with clinician treatment recommendations for patients with a new diagnosis of opioid use disorder	10
“If I had them, I would use them every time”: Perspectives on fentanyl test strip use from people who use drugs	10
C2: editorial board	9
TOC (update)	9
Treatment trajectories and barriers in opioid agonist therapy for people who inject drugs in rural Puerto Rico	9
An evaluation of StaySafe, a tablet app to improve health risk decision-making among people under community supervision	9
Effects of Medicaid Health Homes among people with substance use disorder and another chronic condition on health care utilization and spending: Lessons from New York State	9
Effects of contingency management and use of reminders for drug use treatment on readmission and criminality among young people: A linkage study of a randomized trial	9
Medically treated opioid overdoses among New Jersey Medicaid beneficiaries: Rapid growth and complex comorbidity amid growing fentanyl penetration	9
Characterizing trends in methamphetamine-related health care use when there is no ICD code for “methamphetamine use disorder”	9
Finding a fair deal: Policies on alcohol and drugs at “wet” eldercare facilities	9
Receipt of evidence-based alcohol-related care in a national sample of transgender patients with unhealthy alcohol use: Overall and relative to non-transgender patients	9
“Sobriety equals getting rid of hepatitis C”: A qualitative study exploring the interplay of substance use disorder and hepatitis C among hospitalized adults	9
Alcohol use disorder and associated factors among University of Gondar undergraduate students: A cross-sectional study	9
TOC (update)	9
Drug and alcohol treatment utilization and barriers among Black, American Indian/Alaskan Native, Latine, Asian/Pacific Islander/Native Hawaiian, and White adults: Findings from NESARC-III	9
Low-barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects	9
National trends in buprenorphine prescribing before and during the COVID-19 pandemic	9
TOC (update)	9
Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder	9
Homelessness and publicly funded substance use disorder treatment in California, 2016–2019: Analysis of treatment needs, level of care placement, and outcomes	8
Predicting drug court graduation: Examining the role of individual and programmatic characteristics	8
Examining factors associated with postintervention recidivism in DUI repeat offenders after alcohol treatment: One-year follow-up study	8
Substitution treatment for opioid dependence with slow-release oral morphine: Retention rate, health status, and substance use after switching to morphine	8
Tobacco use among substance use disorder (SUD) treatment staff is associated with tobacco-related services received by clients	8
The phenotype of recovery VIII: Association among delay discounting, recovery capital, and length of abstinence among individuals in recovery from substance use disorders	8
Community coalition and key stakeholder perceptions of the community opioid epidemic before an intensive community-level intervention	8
HealthCall: A randomized trial assessing a smartphone enhancement of brief interventions to reduce heavy drinking in HIV care	8
Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general prac	8
Impact of COVID-19 on service delivery for an evidence-based behavioral treatment for families involved in the child welfare system	8
Strategies to improve implementation of medications for opioid use disorder reported by veterans involved in the legal system: A qualitative study	8
Ethnic discrimination and alcohol-related problem severity among Hispanic/Latin drinkers: The role of social anxiety in the minority stress model	8
Kentucky Women's Justice Community Opioid Innovation Network (JCOIN): A type 1 effectiveness-implementation hybrid trial to increase utilization of medications for opioid use disorder among justice-in	8